

# Lesley A Houghton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4957629/publications.pdf>

Version: 2024-02-01

123  
papers

11,377  
citations

46918

47  
h-index

28224

105  
g-index

125  
all docs

125  
docs citations

125  
times ranked

7715  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e89-e101.	2.4	17
2	Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14268.	1.6	4
3	A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough. <i>ERJ Open Research</i> , 2022, 8, 00546-2021.	1.1	11
4	Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14391.	1.6	8
5	British Society of Gastroenterology guidelines on the management of functional dyspepsia. <i>Gut</i> , 2022, 71, 1697-1723.	6.1	54
6	O61â€¦Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. , 2021, , .		2
7	O63â€¦Gastrointestinal symptom-specific anxiety and symptom severity in irritable bowel syndrome: new insights from factor analysis. , 2021, , .		0
8	The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1189-1200.	0.2	8
9	Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 1485-1494.	0.2	24
10	British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. <i>Gut</i> , 2021, 70, 1214-1240.	6.1	212
11	Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	22
12	Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloatingâ€”a step in the right direction for targeted treatment? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 198-199.	1.9	0
13	Systematic review and network metaâ€”analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 98-108.	1.9	15
14	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8047-8061.	1.6	5
15	Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1179-1192.	1.9	17
16	P326â€¦Identification of novel subgroups in irritable bowel syndrome using latent class analysis: beyond stool form. , 2021, , .		0
17	Longitudinal followâ€”up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1126-1137.	1.9	17
18	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 362-371.	0.2	34

#	ARTICLE	IF	CITATIONS
19	A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles. <i>American Journal of Gastroenterology</i> , 2021, 116, 372-381.	0.2	43
20	Editorial: understanding IBS pathophysiology through “converging channels of research” authors™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1215-1216.	1.9	0
21	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021, 53, 1543-1552.	9.4	96
22	Heartburn as a Marker of the Success of Acid Suppression Therapy in Chronic Cough. <i>Lung</i> , 2021, 199, 597-602.	1.4	6
23	Evaluation of Anorectal Function in Perianal Crohn’s Disease: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5909.	1.0	1
24	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 74-82.	6.1	122
25	Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 392-398.e2.	2.4	78
26	Anxiety-related factors associated with symptom severity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13872.	1.6	30
27	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 1441-1451.	6.1	137
28	Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea “are we any closer?”. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 825-826.	1.9	1
29	Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 517.	0.7	12
30	PWE-076 “Efficacy of Pharmacological Therapies in Patients with Irritable Bowel Syndrome with Diarrhoea: Network Meta-analysis. , 2019, , .		0
31	Unilateral Versus Bilateral Lung Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 284-289.	1.1	7
32	Esophageal dysmotility according to Chicago classification v3.0 vs v2.0: Implications for association with reflux, bolus clearance, and allograft failure post lung transplantation. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13296.	1.6	10
33	Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880559.	1.4	23
34	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 155, 1753-1763.	0.6	119
35	Gastro-oesophageal reflux events: just another trigger in chronic cough?. <i>Gut</i> , 2017, 66, 2047-2048.	6.1	6
36	miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. <i>Scientific Reports</i> , 2017, 7, 14680.	1.6	46

#	ARTICLE	IF	CITATIONS
37	Impaired Esophageal Motility and Clearance Post-Lung Transplant: Risk For Chronic Allograft Failure. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e102.	1.3	51
38	Phenotyping of subjects for large scale studies on patients with <scp>IBS</scp>. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1134-1147.	1.6	36
39	Respiratory disease and the oesophagus: reflux, reflexes and microaspiration. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 445-460.	8.2	82
40	Age, Gender, and Women's Health and the Patient. <i>Gastroenterology</i> , 2016, 150, 1332-1343.e4.	0.6	77
41	Fundamentals of Neurogastroenterology: Physiology/Motility " Sensation. <i>Gastroenterology</i> , 2016, 150, 1292-1304.e2.	0.6	103
42	No association between the common calcium-sensing receptor polymorphism rs1801725 and irritable bowel syndrome. <i>BMC Medical Genetics</i> , 2015, 16, 110.	2.1	3
43	Weak peristalsis with large breaks in chronic cough: association with poor esophageal clearance. <i>Neurogastroenterology and Motility</i> , 2015, 27, 431-442.	1.6	35
44	A meta-analysis of immunogenetic Case-Control Association Studies in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2015, 27, 717-727.	1.6	35
45	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015, 64, 1774-1782.	6.1	97
46	Gas and Bloating. , 2015, , 113-123.		1
47	Irritable Bowel Syndrome in Middle-Aged and Elderly Palestinians: Its Prevalence and Effect of Location of Residence. <i>American Journal of Gastroenterology</i> , 2014, 109, 723-739.	0.2	5
48	Changes of the human gut microbiome induced by a fermented milk product. <i>Scientific Reports</i> , 2014, 4, 6328.	1.6	217
49	The oesophagus and cough: laryngo-pharyngeal reflux, microaspiration and vagal reflexes. <i>Cough</i> , 2013, 9, 12.	2.7	47
50	Rome III Functional Constipation and Irritable Bowel Syndrome With Constipation Are Similar Disorders Within a Spectrum of Sensitization, Regulated by Serotonin. <i>Gastroenterology</i> , 2013, 145, 749-757.	0.6	106
51	Acknowledgements. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 289-289.	1.4	11
52	Gastro-oesophageal reflux and cough. <i>Journal of the Association of Physicians of India</i> , The, 2013, 61, 17-9.	0.0	1
53	Editorial: Breaking the Sound Barrier? Pitfalls and Benefits of Acoustic Cough Monitoring. <i>American Journal of Gastroenterology</i> , 2012, 107, 1833-1836.	0.2	4
54	Chronic Cough. <i>Chest</i> , 2012, 142, 958-964.	0.4	75

#	ARTICLE	IF	CITATIONS
55	Alpha 2 Delta ( $\alpha 2\delta$ ) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome. <i>Frontiers in Pharmacology</i> , 2011, 2, 28.	1.6	49
56	A Novel Approach to Studying the Relationship Between Subjective and Objective Measures of Cough. <i>Chest</i> , 2011, 139, 569-575.	0.4	40
57	GERD-Related Cough: Pathophysiology and Diagnostic Approach. <i>Current Gastroenterology Reports</i> , 2011, 13, 247-256.	1.1	24
58	Bloating in constipation: Relevance of intraluminal gas handling. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 141-150.	1.0	9
59	5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene and irritable bowel syndrome: effect of bowel habit and sex. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 856-861.	0.8	42
60	New Developments in Reflux-Associated Cough. <i>Lung</i> , 2010, 188, 81-86.	1.4	29
61	Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 291-305.	1.4	12
62	Acoustic Cough-Reflux Associations in Chronic Cough: Potential Triggers and Mechanisms. <i>Gastroenterology</i> , 2010, 139, 754-762.	0.6	177
63	Bloating and Distension in Irritable Bowel Syndrome: The Role of Gastrointestinal Transit. <i>American Journal of Gastroenterology</i> , 2009, 104, 1998-2004.	0.2	85
64	Clinical trial: the effects of a fermented milk product containing <i>Bifidobacterium lactis</i> DN-173101 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 104-114.	1.9	289
65	5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 919-929.	1.9	26
66	Measurement of serotonin in platelet depleted plasma by liquid chromatography tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 2163-2167.	1.2	29
67	Bloating and Distention in Irritable Bowel Syndrome: The Role of Visceral Sensation. <i>Gastroenterology</i> , 2008, 134, 1882-1889.	0.6	96
68	First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. <i>Human Molecular Genetics</i> , 2008, 17, 2967-2977.	1.4	173
69	Effect of a second-generation $\alpha 2\delta$ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. <i>Gut</i> , 2007, 56, 1218-1225.	6.1	174
70	Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. <i>Neurogastroenterology and Motility</i> , 2007, 19, 724-731.	1.6	38
71	Effect of the NK3receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. <i>Neurogastroenterology and Motility</i> , 2007, 19, 732-743.	1.6	41
72	The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 313-327.	1.0	12

#	ARTICLE	IF	CITATIONS
73	Altered 5-Hydroxytryptamine Signaling in Patients With Constipation- and Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2006, 130, 34-43.	0.6	304
74	Functional Bowel Disorders. <i>Gastroenterology</i> , 2006, 130, 1480-1491.	0.6	4,197
75	Relationship of Abdominal Bloating to Distention in Irritable Bowel Syndrome and Effect of Bowel Habit. <i>Gastroenterology</i> , 2006, 131, 1003-1010.	0.6	124
76	Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: Two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers. <i>Clinical Therapeutics</i> , 2006, 28, 569-581.	1.1	3
77	Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 183-205.	1.9	141
78	Validation of the measurement of low concentrations of 5-hydroxytryptamine in plasma using high performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 832, 173-176.	1.2	14
79	Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2005, 17, 500-511.	1.6	66
80	Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. <i>Neurogastroenterology and Motility</i> , 2005, 17, 810-820.	1.6	72
81	Diagnostic Criteria for Irritable Bowel Syndrome: Utility and Applicability in Clinical Practice. <i>Digestion</i> , 2004, 70, 210-213.	1.2	64
82	Inter-digestive and post-prandial antro-pyloro-duodenal motor activity in humans: effect of 5-hydroxytryptamine 1 receptor agonism. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 805-815.	1.9	14
83	Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 635-642.	1.9	130
84	Gender differences in plasma 5-hydroxytryptamine (5-HT) concentration in diarrhoea predominant irritable bowel syndrome (d-IBS): Influence of the menstrual cycle. <i>Gastroenterology</i> , 2003, 124, A388.	0.6	7
85	Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. <i>Gut</i> , 2003, 52, 663-670.	6.1	158
86	Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. <i>American Journal of Gastroenterology</i> , 2002, 97, 954-961.	0.2	195
87	A device for 24 hour ambulatory monitoring of abdominal girth using inductive plethysmography. <i>Physiological Measurement</i> , 2002, 23, 661-670.	1.2	25
88	The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. <i>Gut</i> , 2002, 50, 471-474.	6.1	200
89	Visceral sensation and emotion: a study using hypnosis. <i>Gut</i> , 2002, 51, 701-704.	6.1	67
90	Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome. <i>Gut</i> , 2001, 48, 216-220.	6.1	61

#	ARTICLE	IF	CITATIONS
91	Alosetron, a 5-HT <sub>3</sub> receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 775-782.	1.9	118
92	Do male sex hormones protect from irritable bowel syndrome?. <i>American Journal of Gastroenterology</i> , 2000, 95, 2296-2300.	0.2	50
93	Abdominal distension in pre- and post-menopausal females with irritable bowel syndrome (IBS): The effect of the contraceptive pill and hormone replacement therapy. <i>Gastroenterology</i> , 2000, 118, A140.	0.6	1
94	Altered oesophageal motility following the administration of the 5-HT <sub>1</sub> agonist, sumatriptan. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 927-936.	1.9	23
95	5-HT <sub>4</sub> receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1437-1444.	1.9	40
96	Preface. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 1999, 13, vii.	1.0	0
97	Sensory dysfunction and the irritable bowel syndrome. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 1999, 13, 415-427.	1.0	12
98	Opening the doors of perception in the irritable bowel syndrome. <i>Gut</i> , 1997, 41, 567-568.	6.1	17
99	Zamifenacin (UK-76, 654), a potent gut M <sub>3</sub> selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1997, 11, 561-568.	1.9	30
100	Use of hypnotherapy in gastrointestinal disorders. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 525-529.	0.8	10
101	Symptomatology, quality of life and economic features of irritable bowel syndrome—the effect of hypnotherapy. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 91-95.	1.9	126
102	Acute diarrhoea induces rectal sensitivity in women but not men.. <i>Gut</i> , 1995, 37, 270-273.	6.1	24
103	Does the menstrual cycle affect anorectal physiology?. <i>Digestive Diseases and Sciences</i> , 1994, 39, 2607-2611.	1.1	57
104	Is chest pain after sumatriptan oesophageal in origin?. <i>Lancet, The</i> , 1994, 344, 985-986.	6.3	65
105	Physiological effects of emotion: assessment via hypnosis. <i>Lancet, The</i> , 1992, 340, 69-72.	6.3	134
106	Effect of sumatriptan, a new selective 5HT <sub>1</sub> -like agonist, on liquid gastric emptying in man. <i>Alimentary Pharmacology and Therapeutics</i> , 1992, 6, 685-691.	1.9	61
107	Disturbed gastroduodenal motility in patients with active and healed duodenal ulceration. <i>Gastroenterology</i> , 1991, 100, 892-900.	0.6	29
108	Role of the proximal and distal stomach in mixed solid and liquid meal emptying.. <i>Gut</i> , 1991, 32, 615-619.	6.1	153

#	ARTICLE	IF	CITATIONS
109	Relationship between Fluctuations of pH and Pressure in the Human Stomach and Duodenum. <i>Digestive Diseases</i> , 1990, 8, 71-81.	0.8	12
110	Effect of incorporating fat into a liquid test meal on the relation between intragastric distribution and gastric emptying in human volunteers.. <i>Gut</i> , 1990, 31, 1226-1229.	6.1	96
111	Effect of Intraduodenal Infusion of Acid on the Antropyloroduodenal Motor Unit in Human Volunteers. <i>Neurogastroenterology and Motility</i> , 1990, 2, 202-208.	1.6	11
112	DUODENAL BULB ACIDITY AND THE NATURAL HISTORY OF DUODENAL ULCERATION. <i>Lancet, The</i> , 1989, 334, 61-63.	6.3	20
113	Motor mechanisms associated with slowing of the gastric emptying of a solid meal by an intraduodenal lipid infusion. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1989, 4, 437-447.	1.4	171
114	Neural and Hormonal Control of Pyloric Sphincter Function. <i>Scandinavian Journal of Gastroenterology</i> , 1989, 24, 27-31.	0.6	5
115	Physiology of Gastric Emptying and Pathophysiology of Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 1989, 18, 359-373.	1.0	89
116	Physiology of gastric emptying and pathophysiology of gastroparesis. <i>Gastroenterology Clinics of North America</i> , 1989, 18, 359-73.	1.0	33
117	Effect of composition of gastric contents on resistance to emptying of liquids from stomach in humans. <i>Digestive Diseases and Sciences</i> , 1988, 33, 914-918.	1.1	17
118	Effect of meal temperature on gastric emptying of liquids in man.. <i>Gut</i> , 1988, 29, 302-305.	6.1	106
119	Motor activity of the gastric antrum, pylorus, and duodenum under fasted conditions and after a liquid meal. <i>Gastroenterology</i> , 1988, 94, 1276-1284.	0.6	162
120	Relationship of the motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal. <i>Gastroenterology</i> , 1988, 94, 1285-1291.	0.6	214
121	Antropyloroduodenal motor responses to intraduodenal lipid infusion in healthy volunteers. <i>American Journal of Physiology - Renal Physiology</i> , 1988, 254, G671-G679.	1.6	86
122	Effect of food consistency on gastric emptying in man.. <i>Gut</i> , 1987, 28, 1584-1588.	6.1	16
123	A comparative study of the effect of cimetidine and ranitidine on the rate of gastric emptying of liquid and solid test meals in man. <i>Alimentary Pharmacology and Therapeutics</i> , 1987, 1, 401-408.	1.9	29